NSE BSE
cipla stock

Cipla Share Price

- - (%)
Sector: -

694

500087

CIPLA

img img img img
No Data Available

Cipla : Share Price Update


As of the latest trading session, Cipla share price is currently at 1400, which is down by -21.09 from its previous closing. Today, the stock has fluctuated between 1398.15 and 1419.90. Over the past year, Cipla has achieved a return of 54.11 %. In the last month alone, the return has been 3.33 %.

Cipla Performance

Day Range

Low1398.15 High1419.90
1405.90

52 Week Range

Low 911.55 High 1519.00
1405.90

Open Price

1417.10

Prev. Close

1421.10

Volume (Shares)

1094057.00

Total traded value

15381.34

Upper Circuit

1563.20

Lower Circuit

1279.00

Note: The current prices & values are delayed, Login to your account for live updates.

Cipla Fundamentals


(Standalone)

Market Cap (Cr) 113001.10
PE Ratio (TTM) 28.12
Book Value / Share 346.47
Beta 0.22
ROE 10.66%
EPS (TTM) 46.00
Dividend Yield 0.60%
Net Profit Qtr (Cr) 1038.40

Cipla Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 3444.92
Operating Expense 3351.02
Net Profit 1038.40
Net Profit Margin (%) 30.14
Earnings Per Share (EPS) 12.86
EBITDA 1366.50
Effective Tax Rate (%) 19.78
Particulars DEC 2023 (Values in Cr)
Revenue 3798.31
Operating Expense 3169.54
Net Profit 1114.14
Net Profit Margin (%) 29.33
Earnings Per Share (EPS) 14.99
EBITDA 1524.84
Effective Tax Rate (%) 26.28
Particulars SEP 2023 (Values in Cr)
Revenue 3736.46
Operating Expense 3195.48
Net Profit 1029.69
Net Profit Margin (%) 27.55
Earnings Per Share (EPS) 14.17
EBITDA 1430.46
Effective Tax Rate (%) 26.40
Particulars JUN 2023 (Values in Cr)
Revenue 3857.73
Operating Expense 3249.75
Net Profit 895.02
Net Profit Margin (%) 23.20
Earnings Per Share (EPS) 11.09
EBITDA 1362.67
Effective Tax Rate (%) 27.02
Particulars MAR 2023 (Values in Cr)
Revenue 3157.82
Operating Expense 3025.24
Net Profit 355.49
Net Profit Margin (%) 11.25
Earnings Per Share (EPS) 4.40
EBITDA 645.30
Effective Tax Rate (%) 38.81
Particulars MAR 2024 (Values in Cr)
Revenue 14441.14
Operating Expense 12698.03
Net Profit 4077.25
Net Profit Margin (%) 28.23
Earnings Per Share (EPS) 50.51
EBITDA 5554.81
Effective Tax Rate (%) 24.91
Particulars MAR 2023 (Values in Cr)
Revenue 13073.53
Operating Expense 11610.63
Net Profit 2513.47
Net Profit Margin (%) 19.22
Earnings Per Share (EPS) 31.15
EBITDA 3623.77
Effective Tax Rate (%) 28.66
Particulars MAR 2022 (Values in Cr)
Revenue 15052.48
Operating Expense 12243.14
Net Profit 2957.93
Net Profit Margin (%) 19.65
Earnings Per Share (EPS) 36.67
EBITDA 4377.93
Effective Tax Rate (%) 24.22
Particulars MAR 2021 (Values in Cr)
Revenue 11060.17
Operating Expense 8748.99
Net Profit 2468.28
Net Profit Margin (%) 22.31
Earnings Per Share (EPS) 30.61
EBITDA 3297.69
Effective Tax Rate (%) 26.55
Particulars MAR 2020 (Values in Cr)
Revenue 12220.22
Operating Expense 10587.68
Net Profit 2318.17
Net Profit Margin (%) 18.96
Earnings Per Share (EPS) 28.76
EBITDA 3600.14
Effective Tax Rate (%) 21.79
Particulars MAR 2023 (Values in Cr)
Book Value / Share 290.01
ROE % 12.82
ROCE % 17.79
Total Debt to Total Equity 0.04
EBITDA Margin 23.38
Particulars MAR 2022 (Values in Cr)
Book Value / Share 258.33
ROE % 13.07
ROCE % 16.83
Total Debt to Total Equity 0.08
EBITDA Margin 21.37
Particulars MAR 2021 (Values in Cr)
Book Value / Share 227.25
ROE % 14.09
ROCE % 17.39
Total Debt to Total Equity 0.14
EBITDA Margin 23.58
Particulars MAR 2020 (Values in Cr)
Book Value / Share 195.51
ROE % 10.05
ROCE % 12.19
Total Debt to Total Equity 0.23
EBITDA Margin 20.72
Particulars MAR 2019 (Values in Cr)
Book Value / Share 186.33
ROE % 10.33
ROCE % 11.67
Total Debt to Total Equity 0.29
EBITDA Margin 21.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 305.25
ROE % 10.66
ROCE % 14.76
Total Debt to Total Equity 0.00
EBITDA Margin 26.01
Particulars MAR 2022 (Values in Cr)
Book Value / Share 279.05
ROE % 13.94
ROCE % 18.21
Total Debt to Total Equity 0.00
EBITDA Margin 28.95
Particulars MAR 2021 (Values in Cr)
Book Value / Share 247.10
ROE % 13.22
ROCE % 17.18
Total Debt to Total Equity 0.00
EBITDA Margin 32.92
Particulars MAR 2020 (Values in Cr)
Book Value / Share 215.85
ROE % 13.97
ROCE % 17.81
Total Debt to Total Equity 0.00
EBITDA Margin 28.44
Particulars MAR 2019 (Values in Cr)
Book Value / Share 195.88
ROE % 12.63
ROCE % 16.43
Total Debt to Total Equity 0.01
EBITDA Margin 24.89
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1564.62
Total Assets 29463.28
Total Liabilities 29463.28
Total Equity 23713.54
Share Outstanding 807150593
Price to Book Ratio 2.95
Return on Assets (%) 9.50
Return on Capital (%) 11.56
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1928.48
Total Assets 27101.12
Total Liabilities 27101.12
Total Equity 21117.38
Share Outstanding 806814036
Price to Book Ratio 3.65
Return on Assets (%) 9.28
Return on Capital (%) 11.47
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1401.23
Total Assets 25151.89
Total Liabilities 25151.89
Total Equity 18585.59
Share Outstanding 806463279
Price to Book Ratio 3.30
Return on Assets (%) 9.56
Return on Capital (%) 11.82
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1003.91
Total Assets 23662.56
Total Liabilities 23662.56
Total Equity 16057.28
Share Outstanding 806235329
Price to Book Ratio 1.96
Return on Assets (%) 6.53
Return on Capital (%) 8.19
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 618.81
Total Assets 23963.32
Total Liabilities 23963.32
Total Equity 15344.25
Share Outstanding 805701266
Price to Book Ratio 2.70
Return on Assets (%) 6.37
Return on Capital (%) 7.77
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 966.46
Total Assets 27596.47
Total Liabilities 27596.47
Total Equity 24638.09
Share Outstanding 807150593
Price to Book Ratio 2.95
Return on Assets (%) 9.10
Return on Capital (%) 10.2
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1428.03
Total Assets 25449.05
Total Liabilities 25449.05
Total Equity 22513.55
Share Outstanding 806814036
Price to Book Ratio 3.65
Return on Assets (%) 11.62
Return on Capital (%) 13.14
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 874.80
Total Assets 22963.74
Total Liabilities 22963.74
Total Equity 19927.56
Share Outstanding 806463279
Price to Book Ratio 3.30
Return on Assets (%) 10.74
Return on Capital (%) 12.39
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 523.07
Total Assets 20405.66
Total Liabilities 20405.66
Total Equity 17402.96
Share Outstanding 806235329
Price to Book Ratio 1.96
Return on Assets (%) 11.36
Return on Capital (%) 13.32
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 174.56
Total Assets 18418.81
Total Liabilities 18418.81
Total Equity 15781.91
Share Outstanding 805701266
Price to Book Ratio 2.70
Return on Assets (%) 10.25
Return on Capital (%) 11.97
Particulars MAR 2023 (Values in Cr)
Net Income 4220.77
Cash from Operations 4539.54
Cash from Investing -2388.51
Cash from Financing -958.29
Net change in Cash -109.15
Free Cash Flow 5380.07
Particulars MAR 2022 (Values in Cr)
Net Income 3675.39
Cash from Operations 4465.40
Cash from Investing -1871.88
Cash from Financing -1599.79
Net change in Cash -145.77
Free Cash Flow 5009.50
Particulars MAR 2021 (Values in Cr)
Net Income 3290.06
Cash from Operations 4792.63
Cash from Investing -2387.18
Cash from Financing -1239.51
Net change in Cash 128.51
Free Cash Flow 5422.29
Particulars MAR 2020 (Values in Cr)
Net Income 2178.18
Cash from Operations 3916.70
Cash from Investing 104.04
Cash from Financing -2948.82
Net change in Cash 223.67
Free Cash Flow 4489.46
Particulars MAR 2019 (Values in Cr)
Net Income 2079.14
Cash from Operations 2284.38
Cash from Investing -1668.68
Cash from Financing -348.72
Net change in Cash -326.25
Free Cash Flow 2644.46
Particulars MAR 2023 (Values in Cr)
Net Income 3685.17
Cash from Operations 4119.31
Cash from Investing -2757.95
Cash from Financing -424.77
Net change in Cash -147.67
Free Cash Flow 4705.71
Particulars MAR 2022 (Values in Cr)
Net Income 3905.08
Cash from Operations 3707.46
Cash from Investing -2463.73
Cash from Financing -426.72
Net change in Cash -117.02
Free Cash Flow 4012.50
Particulars MAR 2021 (Values in Cr)
Net Income 3350.66
Cash from Operations 4412.26
Cash from Investing -3360.45
Cash from Financing -65.80
Net change in Cash 34.06
Free Cash Flow 4929.23
Particulars MAR 2020 (Values in Cr)
Net Income 2964.31
Cash from Operations 2683.12
Cash from Investing -1126.33
Cash from Financing -693.89
Net change in Cash 197.92
Free Cash Flow 3132.83
Particulars MAR 2019 (Values in Cr)
Net Income 2492.83
Cash from Operations 1919.43
Cash from Investing -1147.05
Cash from Financing -473.32
Net change in Cash -152.32
Free Cash Flow 2231.48
Company Name Price P/E P/B Market Cap 52 Week Low/High
CIPLA LTD 1420.05 26.93 4.29 114654.12 911.80 / 1519.00
BLISS GVS PHARMA LTD 109.15 11.93 1.18 1142.70 71.00 / 148.95
FERMENTA BIOTECH LIMITED 160.95 0.00 1.65 473.69 132.30 / 214.00
GLAXOSMITHKLINE PHARMA LT 2023.85 53.46 22.26 34285.24 1265.00 / 2649.95
SANOFI INDIA LIMITED 8570.70 34.79 19.44 19738.32 6253.40 / 9370.35
Company Name Price P/E P/B Market Cap 52 Week Low/High
CIPLA LTD 1420.05 30.87 4.09 114654.12 911.80 / 1519.00
AMRUTAJAN HEALTH LTD 749.30 49.23 8.26 2166.27 556.05 / 802.60
ASTRAZENECA PHARMA IND LT 5639.25 88.39 21.52 14098.13 3131.10 / 7208.00
BLISS GVS PHARMA LTD 109.15 15.08 1.15 1142.70 71.00 / 148.95
ABBOTT INDIA LIMITED 26545.40 46.96 15.25 56408.98 20594.25 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1394.00
  • 26 Days 1400.20
  • 10 Days 1396.30
  • 50 Days 1422.20
  • 12 Days 1395.20
  • 100 Days 1387.80
  • 20 Days 1389.10
  • 200 Days 1100.80
1407.28
PIVOT
First Resistance 1427.87
Second Resistance 1449.03
Third Resistance 1469.62
First Support 1386.12
Second Support 1365.53
Third Support 1344.37
RSI 52.34
MACD -4.99
Commodity Channel Index (CCI) 67.44
ADX 37.66
Williams % R -11.05

Over 1 Month

down

3.33

Over 3 Months

down

-1.36

Over 6 Months

down

15.08

Over 1 Year

down

54.11

Over 3 Years

down

17.26

Over 5 Years

down

20.89

Cipla Future

Future: Price

30 May
1410.00
27 Jun
1420.50
25 Jul
1430.85
25 May
0 100 200 300 400 500 600

Discount/Premium

30 May
3.30
27 Jun
13.80
25 Jul
24.15
25 May
0 1 2 3 4 5 6 7

Active Calls

1400.0
23557
1420.0
19852
1440.0
17212
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1300.0
10903
1400.0
10732
1360.0
7809
25 Jul
0 500 1000 1500 2000 2500

Cipla Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
23.87
Promoter Holdings
33.46
FII
25.82
DII
16.82
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Yusuf Khwaja Hameid Shareholding of Promoter and Promoter Group 1.50521183E8 18.68
Sophie Ahmed Shareholding of Promoter and Promoter Group 4.5982E7 5.71
Hdfc Mutual Fund Public Shareholding 3.5993491E7 4.47
Sbi Mutual Fund Public Shareholding 3.4079873E7 4.23
Lic Public Shareholding 2.9568683E7 3.67
M K Hamied Shareholding of Promoter and Promoter Group 2.784432E7 3.46
Government Pension Fund Global Public Shareholding 1.9014244E7 2.36
Samina Hamied Shareholding of Promoter and Promoter Group 1.79095E7 2.22
Nps Trust Public Shareholding 1.3352547E7 1.66
Kamil Hamied Shareholding of Promoter and Promoter Group 1.09395E7 1.36
Rumana Hamied Shareholding of Promoter and Promoter Group 9886500.0 1.23
Uti Public Shareholding 8903623.0 1.11
Shirin Hamied Shareholding of Promoter and Promoter Group 6363000.0 0.79
Okasa Pharma Private Limited Shareholding of Promoter and Promoter Group 189375.0 0.02
Farida Hamied Shareholding of Promoter and Promoter Group 0.0 0.0
Hamsons Laboratories Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Alps Remedies Private Limited Shareholding of Promoter and Promoter Group 0.0 0.0
Shree Riddhi Chemicals Llp Shareholding of Promoter and Promoter Group 0.0 0.0
Mn Rajkumar Garments Llp Shareholding of Promoter and Promoter Group 0.0 0.0

Cipla

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-07-21 8.5 Final 2023-07-21 Equity shares 2022-08-08 5.0 Final 2022-08-10 Equity shares 2021-08-09 5.0 Final 2021-08-11 Equity shares 2020-03-19 3.0 Interim 2020-03-20 Equity shares 2020-03-19 1.0 Special 2020-03-20 Equity shares 2019-07-31 3.0 Final 2019-08-02 Equity shares 2018-08-13 3.0 Final 2018-08-16 Equity shares 2017-07-26 2.0 Final 2017-07-28 Equity shares 2016-09-12 2.0 Final 2016-09-15 Equity shares 2015-08-11 2.0 Final 2015-08-13 Equity shares 2014-08-06 2.0 Final 2014-08-08 Equity shares 2013-08-06 2.0 Final 2013-08-08 Equity shares 2012-08-01 2.0 Final 2012-08-03 Equity shares 2011-08-09 2.0 Final 2011-08-11 Equity shares 2010-09-03 0.8 Interim 2010-09-06 Equity shares 2010-07-23 2.0 Final 2010-07-27 Equity shares 2009-08-10 2.0 Final 2009-08-12 Equity shares 2008-08-12 2.0 Final 2008-08-14 Equity shares 2007-08-08 2.0 Final 2007-08-10 Equity shares 2006-08-18 0.0 Final 2006-08-22 Equity shares 2005-08-19 0.0 Final 2005-08-23 Equity shares
Ex-Date Ex-Bonus Ratio
2006-04-25 2006-04-24 3:2 1999-11-05 1999-10-18 2:1
Ex-Date Old FV NEW FV Record Date
2004-05-11 10.0 2.0 2004-05-19

Learn More About Stocks

Cipla Limited Overview

Cipla, established in 1990, is a leading pharmaceutical entity in India, holding significant market positions in therapies like respiratory and urology, and a broad product portfolio of over 1,500 products across 65 therapeutic categories. With a strong footprint in India and a significant presence in emerging markets, Cipla has become the 3rd largest pharmaceutical company in India and a major exporter. The company's expertise in manufacturing generic APIs, with over 200 generics supplied to 62 countries, underlines its role as a preferred partner globally. Cipla's manufacturing prowess is supported by 47 state-of-the-art facilities across six countries, enabling a diversified product range from antidepressants to antivirals. Strategic partnerships for COVID-19 treatments with major pharmaceutical companies, acquisitions to bolster renewable energy initiatives, and a joint venture for biologic product development illustrate Cipla's forward-looking approach. With subsidiaries streamlined for operational efficiency and a scheme of arrangement to optimise its business structure, Cipla invests heavily in R&D, underscoring its commitment to innovation. As it aims to expand its lung specialty offerings, Cipla continues to deepen its focus on antidiabetics and oncology, aiming to partner with global corporations to enhance its market reach and therapeutic impact.

About Cipla

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by Cipla

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Cipla Ltd?

Answer Field

The share price of Cipla Ltd for NSE is ₹ 1400 and for BSE is ₹ 0.

What is the Market Cap of Cipla Ltd?

Answer Field

The market cap of Cipla Ltd for NSE is ₹ 1,13,001.10 Cr. and for BSE is ₹ 0.00 Cr. as of now.

What is the 52 Week High and Low of Cipla Ltd?

Answer Field

The 52 Week High and Low of Cipla Ltd for NSE is ₹ 1519.00 and ₹ 911.55 and for BSE is ₹ 1519.00 and ₹ 911.80.

How to Buy Cipla Ltd share?

Answer Field

You can trade in Cipla Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Cipla Ltd?

Answer Field

The 1 year returns on the stock has been 54.11%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7 Lac+ Users

icon-with-text

4.3 App Rating

icon-with-text

4 Languages

icon-with-text

₹ 3800 Cr MTF Book

icon-with-text
loader